The treatment of infertility in polycystic ovary syndrome: a brief update
Date
2012
Authors
Costello, M.
Misso, M.
Wong, J.
Hart, R.
Rombauts, L.
Melder, A.
Norman, R.
Teede, H.
Editors
Advisors
Journal Title
Journal ISSN
Volume Title
Type:
Journal article
Citation
Australian and New Zealand Journal of Obstetrics and Gynaecology, 2012; 52(4):400-403
Statement of Responsibility
Michael F. Costello, Marie L. Misso, Jennifer Wong, Roger Hart, Luk Rombauts, Angela Melder, Robert J. Norman and Helen J. Teede
Conference Name
Abstract
Polycystic ovary syndrome (PCOS) is the most common cause of anovulatory infertility. Lifestyle change alone is considered the first-line treatment for the management of infertile anovulatory PCOS women who are overweight or obese. First-line medical ovulation induction therapy to improve fertility outcomes is clomiphene citrate, whilst gonadotrophins, laparoscopic ovarian surgery or possibly metformin are second line in clomiphene citrate-resistant PCOS women. There is currently insufficient evidence to recommend aromatase inhibitors over that of clomiphene citrate in infertile anovulatory PCOS women in general or specifically in therapy naive or clomiphene citrate-resistant PCOS women. IVF/ICSI treatment is recommended either as a third-line treatment or in the presence of other infertility factors.
School/Discipline
Dissertation Note
Provenance
Description
Access Status
Rights
© 2012 The Authors ANZJOG © 2012 The Royal Australian and New Zealand College of Obstetricians and Gynaecologists